Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.
Conditions
Interventions
Desvenlafaxine
Omega 3 Fatty acids
+1 more
Locations
1
United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Start Date
February 1, 2013
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
December 27, 2017
NCT07190248
NCT00001987
NCT07486219
NCT07485114
NCT07336732
NCT03191149
Lead Sponsor
UConn Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions